Roche Holdings AG (RHHBY) just dropped some encouraging numbers from its Phase 2 obesity drug trial, and the results suggest it might have a real contender in the increasingly crowded weight-loss medication space.

The Swiss pharmaceutical giant released topline data on Tuesday from its CT388-103 Phase 2 trial evaluating CT-388, an investigational once-weekly injectable that targets both GLP-1 and GIP receptors. The drug is being developed not just for obesity, but also for type 2 diabetes and related conditions that often come along for the ride.

What the Numbers Show

The 469-patient trial tested CT-388 at low, middle, and high doses in adults with obesity (BMI of 30 or higher) or those who were overweight (BMI between 27 and 30) with at least one weight-related health issue. Importantly, participants didn't have type 2 diabetes. Researchers evaluated five different dosing approaches, with 24mg being the highest dose tested over 48 weeks.

Here's where things get interesting. Patients on the highest dose (24mg) saw placebo-adjusted weight loss of 22.5% without hitting a plateau at the 48-week mark. That lack of plateau matters because it suggests people might continue losing weight beyond the study period.

The trial showed a clear dose-response relationship, meaning higher doses delivered better results. Using the treatment regimen estimand, placebo-adjusted weight loss came in at 18.3%.

Breaking down the 24mg dose results: 95.7% of participants lost more than 5% of their body weight, 87% lost over 10%, nearly half (47.8%) shed more than 20%, and 26.1% achieved weight loss exceeding 30%. Those are substantial numbers by any measure.

There's a metabolic health bonus too. Among participants who were pre-diabetic at baseline and received the 24mg dose, 73% achieved normal blood glucose levels at week 48. The placebo group? Just 7.5%.

Safety Profile Looks Manageable

The drug was generally well-tolerated, with most gastrointestinal side effects being mild to moderate. That's pretty standard for this class of medications, which includes established players in the weight-loss market. Treatment discontinuation due to adverse events stayed low at 5.9% in the CT-388 groups versus 1.3% in the placebo arm.

The Bigger Picture

CT-388 came into Roche's portfolio through its 2023 acquisition of Carmot Therapeutics. Since then, Roche has designated it a fast-track asset and accelerated its clinical development timeline considerably.

The company is currently running an additional Phase 2 study (CT388-104) evaluating CT-388 in obese patients who do have type 2 diabetes. The Phase 3 clinical trial program for obesity (Enith1 and Enith2) is expected to kick off this quarter.

Roche emphasized Tuesday that beyond its standalone potential, CT-388 plays a strategic role in its broader obesity pipeline and is viewed as a combination asset alongside petrelintide, another drug in its development portfolio.

The stakes are high. Last September, Roche outlined its ambitions to become a leading player in the booming weight-loss drug market, setting up a competitive showdown with Eli Lilly and Co. (LLY) and Novo Nordisk A/S (NVO), the current heavyweights dominating the space.

Price Action: RHHBY stock closed at $56.12 on Monday.